Wall Street Week: Concerns About Tariffs and Hope on Cancer
Welcome to the Wall Street Week newsletter, bringing you stories of capitalism about things you need to know, but even more ...
Pfizer Falls on RFK’s Progress Towards Confirmation Despite Good Earnings. Its CEO is Unbothered.
CEO Albert Bourla says Pfizer has met the strategic goals it had set for itself in 2024, and that it was ‘executing ...
The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck
Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.
Pfizer CEO ‘disappointed’ by Robert Kennedy’s refusal to rebut claims on vaccine risks
Pfizer’s chief executive said he was “disappointed” with Robert F Kennedy Jr’s refusal to disavow the debunked link between vaccines and autism, even as he expressed confidence that the Trump ...
Pfizer CEO: Our stock is very cheap with lots of upside potential
In an interview on CNBC’s Mad Money, Dr. Albert Bourla said Pfizer (PFE) is focusing on business development to create shareholder value. “We ...
Zepbound sales double, tariffs could hit Ozempic, and Pfizer on RFK Jr.: Pharma news roundup
Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled in the fourth quarter year over year, despite ...
Pfizer shows profit growth from cost cuts and steadier COVID sales
Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...
Pfizer Is About to Report Its Earnings. The Stock Has Been Floundering.
The CEO said last month that the drugmaker had cut costs, revamped its sales operation, and made other big fixes.